In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Prostate cancer (PCa) is one of the most frequently diagnosed malignancies in men. Androgen-deprivation therapy (ADT) is the first-line treatment and fundamental management for men with advanced ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

A protein called the androgen receptor normally functions to guide the development of the prostate—signaling the cells to stop growing, act as normal prostate cells and maintain a healthy state.

Expression studies on thyroid tumors indicate that they express ER and possibly progesterone receptors and androgen receptors ... and evaluation of the signaling pathways by which estrogen ...

While most prostate cancers initially respond to androgen ... receptor therapies like enzalutamide. Furthermore, since TGF-β is associated with immune suppression in tumors, inhibiting this ...